文章：

复发或难治性弥漫性大B细胞淋巴瘤患者在CAR-T细胞治疗后使用Loncastuximab tesirine的疗效结局

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

原文发布日期：2024-11-28

DOI: 10.1038/s41408-024-01195-4

类型: Article

开放获取: 是

英文摘要：

The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age ≥ 18 years) with R/R DLBCL who received lonca monotherapy as third- (3 L) or fourth line (4 L) treatment after progressing on second line (2 L) or 3 L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2 L CAR-T (median age:66 years; 61% male) and 23 following 3 L CAR-T (median age:57 years; 43% male). Patients with 2 L CAR-T/3 L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3 L CAR-T/4 L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R/R DLBCL in 3 L and 4 L settings including those who were resistant to or progressed after CAR-T.
 

摘要翻译： 

氯喹珠单抗tesirine（lonca）在嵌合抗原受体T细胞疗法（CAR-T）进展或失败后的疗效尚不明确。因此，本研究旨在探讨美国复发或难治性弥漫性大B细胞淋巴瘤患者在CAR-T治疗后接受lonca的真实世界应用情况及临床结局。这项回顾性研究纳入了接受lonca单药作为三线或四线治疗的成年（年龄≥18岁）复发或难治性弥漫性大B细胞淋巴瘤患者，这些患者分别在二线或三线CAR-T治疗后出现进展。CAR-T后lonca治疗的结局指标包括缓解率（总体缓解率和完全缓解率）、缓解持续时间、无进展生存期和总生存期。共118例患者纳入分析，其中95例在二线CAR-T后接受lonca（中位年龄66岁；男性占61%），23例在三线CAR-T后接受lonca（中位年龄57岁；男性占43%）。二线CAR-T/三线lonca患者的总体缓解率为73%（完全缓解率为34%）。中位随访8.5个月后，缓解持续时间、无进展生存期和总生存期的中位数均未达到。12个月时的缓解持续时间、无进展生存期和总生存率分别为68%、77%和84%。三线CAR-T/四线lonca患者的总体缓解率为78%（完全缓解率为17%）。中位随访13个月后，缓解持续时间和无进展生存期的中位数分别为7.6个月和12.0个月，总生存期中位数未达到。12个月总生存率为95%。本研究表明，对于包括CAR-T耐药或治疗后进展的复发或难治性弥漫性大B细胞淋巴瘤患者，lonca单药治疗在三线和四线治疗中是一种有效的治疗选择。

原文链接：

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma